US · KZIA
Kazia Therapeutics Limited
- Sector
- Healthcare · Biotechnology
- Headquarters
- Sydney, NSW 2000
- Website
- kaziatherapeutics.com
Price · as of 2025-06-30
$13.39
Market cap 13.69M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $10.50 | -21.58% |
| Intrinsic Value(DCF) | $3.10 | -76.85% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $1,062.00 | +7,831.29% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $250.16 | $15,876.08 | $0.00 | $0.00 | $13,457.50 |
| 2012 | $132.98 | $38,842.71 | $0.00 | $304.20 | $1,121.50 |
| 2013 | $754.00 | $509,616.09 | $35.13 | $0.00 | $1,280.70 |
| 2014 | $684.00 | $20,716.20 | $0.00 | $0.00 | $11,806.60 |
| 2015 | $496.00 | $232.83 | $450.17 | $118.10 | $0.00 |
| 2016 | $408.00 | $1,830.87 | $759.00 | $0.00 | $0.00 |
| 2017 | $152.50 | $152.95 | $1,120,581.45 | $0.00 | $0.00 |
| 2018 | $157.50 | $1,874.65 | $19.06 | $0.00 | $3,420.90 |
| 2019 | $123.00 | $1,646.88 | $17.42 | $0.00 | $4,261.70 |
| 2020 | $367.50 | $5,394.02 | $5.18 | $0.00 | $0.00 |
| 2021 | $531.50 | $438.11 | $1,313,941.45 | $0.00 | $0.00 |
| 2022 | $75.50 | $360.71 | $0.00 | $0.00 | $5,410.20 |
| 2023 | $52.50 | $617.91 | $0.00 | $0.00 | $2,987.50 |
| 2024 | $18.50 | $41,822.10 | $0.00 | $0.00 | $0.00 |
| 2025 | $7.76 | $16.09 | $0.00 | $0.00 | $1,062.00 |
AI valuation
Our deep-learning model estimates Kazia Therapeutics Limited's (KZIA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $10.50
- Current price
- $13.39
- AI upside
- -21.58%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.10
-76.85% upside
Graham-Dodd
—
— upside
Graham Formula
$1,062.00
+7,831.29% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| KZIA | Kazia Therapeutics Limite… | $13.39 | 13.69M | +20% | -77% | — | +7,831% | -0.63 | -1.56 | 309.03 | -0.68 | — | -1.38 | 100.00% | -33850.00% | -49290.48% | 226.03% | 112.59% | -149.76% | -0.05 | — | 0.35 | 0.32 | 0.30 | -6564.00% | -9818.00% | 3859.00% | -102.30% | -0.94 | 114.02% | 0.00% | 0.00% | 22.54% | -0.64 | -0.68 | 215.01 | -40.14 |
| BDRX | Biodexa Pharmaceuticals P… | $1.08 | 90.59K | +65,720% | — | — | — | -0.25 | 0.17 | — | -0.05 | -0.06 | 0.53 | 0.00% | — | — | -88.14% | -269.10% | -45.25% | 0.09 | — | 1.75 | 0.47 | 0.10 | 40524.00% | -10000.00% | 8388.00% | -924.24% | -2.44 | -397.95% | 0.00% | 0.00% | 0.00% | -0.05 | -0.04 | — | -15.86 |
| CMND | Clearmind Medicine Inc. | $1.13 | 154.43K | — | — | — | — | -0.08 | 0.25 | — | 0.94 | — | 0.27 | 0.00% | — | — | -180.28% | 180.16% | -58.05% | 1.49 | -290.07 | 1.22 | 1.21 | 0.58 | -5494.00% | — | -189.00% | -1590.11% | -0.97 | 150.51% | 0.00% | 0.00% | 0.00% | 0.62 | 0.74 | — | -9.25 |
| CNSP | CNS Pharmaceuticals, Inc. | $3.11 | 1.79M | — | — | — | — | -0.68 | 1.63 | — | -0.27 | — | 1.63 | 0.00% | — | — | -1703.39% | 642.50% | -285.68% | 0.05 | -924.50 | 3.43 | 2.91 | 0.41 | -3522.00% | — | 2102.00% | -169.67% | -6.78 | 738.03% | 0.00% | 0.00% | 58.36% | -0.27 | -0.23 | — | -15.99 |
| GRI | GRI Bio, Inc. | $2.55 | 229.07K | +6,695% | — | — | — | -0.02 | 0.04 | — | 0.66 | — | 0.04 | 0.00% | — | — | -238.17% | 791.34% | -166.00% | 0.01 | — | 3.25 | 3.11 | 0.68 | -9212.00% | -10000.00% | 1833.00% | -4086.53% | -3.85 | 673.21% | 0.00% | 0.00% | 1303.49% | 0.66 | 0.78 | — | -12.03 |
| INM | InMed Pharmaceuticals Inc… | $0.85 | 1.54M | +1,918% | +653% | — | — | -0.25 | 0.11 | 0.42 | 1.66 | — | 0.13 | 34.53% | -160.20% | -165.14% | -52.84% | -173.20% | -43.65% | 0.06 | -21.22 | 6.99 | 6.27 | 1.94 | -5848.00% | 750.00% | 1103.00% | -377.16% | -3.10 | -169.90% | 0.00% | 0.00% | 311.23% | 1.52 | 1.55 | -2.43 | -10.26 |
| SILO | Silo Pharma, Inc. | $0.37 | 2.92M | +5,090% | +86% | — | — | -1.09 | 0.95 | 66.36 | 0.52 | — | 1.00 | 91.90% | -6526.44% | -6092.59% | -78.37% | 266.27% | -57.96% | 0.00 | -925.59 | 4.29 | 4.28 | 0.89 | -83.00% | 0.00% | 1890.00% | -80.13% | -2.32 | 216.94% | 0.00% | 0.00% | 11.59% | 0.49 | 0.60 | -31.84 | -2.88 |
| SNGX | Soligenix, Inc. | $1.18 | 11.9M | — | — | — | — | -0.48 | 0.96 | — | 0.25 | — | 0.96 | 0.00% | — | — | -248.97% | 387.20% | -88.11% | 0.36 | — | 1.82 | 1.61 | 0.67 | -6066.00% | — | -233.00% | -213.60% | -1.73 | 361.77% | 0.00% | 0.00% | 35.16% | 0.25 | 0.29 | — | -38.99 |
About Kazia Therapeutics Limited
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
- CEO
- John Edwin Friend
- Employees
- 9
- Beta
- 1.78
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.10 ÷ $13.39) − 1 = -76.85% (DCF, example).